BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27717710)

  • 1. Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?
    Michalak EM; Visvader JE
    Mol Oncol; 2016 Dec; 10(10):1497-1515. PubMed ID: 27717710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.
    Liu L; Kimball S; Liu H; Holowatyj A; Yang ZQ
    Oncotarget; 2015 Feb; 6(4):2466-82. PubMed ID: 25537518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PELP1 oncogenic functions involve CARM1 regulation.
    Mann M; Cortez V; Vadlamudi R
    Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of histone modifications and variants in regulating gene expression in breast cancer.
    Dalvai M; Bystricky K
    J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):19-33. PubMed ID: 20131086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histone methyltransferases: a new class of therapeutic targets in cancer treatment?].
    Chaib H; Prébet T; Vey N; Collette Y
    Med Sci (Paris); 2011; 27(8-9):725-32. PubMed ID: 21880260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
    Zagni C; Chiacchio U; Rescifina A
    Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in histone methyltransferases and histone demethylases].
    Wang X; Zhu WG
    Ai Zheng; 2008 Oct; 27(10):1018-25. PubMed ID: 18851779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence-based methods for screening writers and readers of histone methyl marks.
    Allali-Hassani A; Wasney GA; Siarheyeva A; Hajian T; Arrowsmith CH; Vedadi M
    J Biomol Screen; 2012 Jan; 17(1):71-84. PubMed ID: 21972038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Histone Methylation in Cancer.
    McCabe MT; Mohammad HP; Barbash O; Kruger RG
    Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein arginine methyltransferases: promising targets for cancer therapy.
    Hwang JW; Cho Y; Bae GU; Kim SN; Kim YK
    Exp Mol Med; 2021 May; 53(5):788-808. PubMed ID: 34006904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
    Mohammad HP; Barbash O; Creasy CL
    Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone lysine methyltransferases as anti-cancer targets for drug discovery.
    Liu Q; Wang MW
    Acta Pharmacol Sin; 2016 Sep; 37(10):1273-1280. PubMed ID: 27397541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes.
    Bouchard C; Sahu P; Meixner M; Nötzold RR; Rust MB; Kremmer E; Feederle R; Hart-Smith G; Finkernagel F; Bartkuhn M; Savai Pullamsetti S; Nist A; Stiewe T; Philipsen S; Bauer UM
    Cell Rep; 2018 Sep; 24(12):3339-3352. PubMed ID: 30232013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins.
    Tryndyak VP; Kovalchuk O; Pogribny IP
    Cancer Biol Ther; 2006 Jan; 5(1):65-70. PubMed ID: 16322686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
    Chiang K; Zielinska AE; Shaaban AM; Sanchez-Bailon MP; Jarrold J; Clarke TL; Zhang J; Francis A; Jones LJ; Smith S; Barbash O; Guccione E; Farnie G; Smalley MJ; Davies CC
    Cell Rep; 2017 Dec; 21(12):3498-3513. PubMed ID: 29262329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and function of histone methyltransferases.
    Trievel RC
    Crit Rev Eukaryot Gene Expr; 2004; 14(3):147-69. PubMed ID: 15248813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
    Patani N; Jiang WG; Newbold RF; Mokbel K
    Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.